Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors.
Delord JP, Italiano A, Awada A, Aftimos P, Houédé N, Lebbé C, Pages C, Lesimple T, Dinulescu M, Schellens JHM, Leijen S, Rottey S, Kruse V, Kefford R, Faivre S, Gomez-Roca C, Scheuler A, Massimini G, Raymond E.
Delord JP, et al.
Target Oncol. 2021 Jan;16(1):37-46. doi: 10.1007/s11523-020-00768-0.
Target Oncol. 2021.
PMID: 33170484
Clinical Trial.
DLTs were mainly observed at doses 120 mg/day and included skin rash/acneiform dermatitis and ocular events, such as serous retinal detachment. ...CONCLUSIONS: Based on the safety profile and efficacy signals, a continuous bid regimen was the preferred dosing schedu …
DLTs were mainly observed at doses 120 mg/day and included skin rash/acneiform dermatitis and ocular events, such as serous re …